February 22, 2022 4:55pm

It could get worse until its better forget finding a bottom in the midst of chaos and uncertainty?

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares jumping on “sudden” volume by 11 a.m. of 4,225 shares traded popping the stock +$0.62 after Friday trading down -$0.68 with 103 shares traded

News: Homology Medicines (FIXX -$1.26 or -32.64% to $2.60 with 3.639 m shares traded, 3-month average 460.3 K) An FDA clinical hold letter is expected within 30 days re pheNIX gene therapy trial of HMI-102.The reason for the clinical hold is the observations of elevated liver function tests. Thus, there is a need to modify risk mitigation measures in the study.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

 

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -482.57 points (-1.42%); the S&P closed DOWN -44.11 points (-1.01%) while the Nasdaq closed DOWN -166.55 points (-1.23%)

 

Henry’omics:

U.S. stocks dived at the open Tuesday with the Nasdaq opening -1% lower and kept going down.

At its session low, the Dow had lost more than 700 points.

 

Economic Data Docket: The S&P CoreLogic Case-Shiller home price index of 20 metropolitan areas surged 18.6% unadjusted in December from a year earlier and 1.1% from the previous month. The Conference Board's consumer confidence index for February was nearly unchanged from the previous month at 110.5. The IHS Markit purchasing managers index, a gauge of private sector output, climbed to 56.0, above forecasts and a two-month high. The services business index climbed to 56.7, while the manufacturing PMI rose to 57.5.

 

52-week lows:

  • Adverum Biotechnologies (ADVM) all-time low of $1.33
  • Fate therapeutics (FATE) all-time low of $32.57
  • Editas Medicine (EDIT) all-time low of $18.84
  • Solid BioSciences (SLDB) all-time low of $0.90
  • Cellectis SA (CLLS) all-time low of $4.70
  • Homology Medicine (FIXX) all-time low of $2.74
  • Verastem (VSTM) all-time low of $1.22

 

RegMed Investors’ (RMi) pre-open: “rolling in chaos and uncertainty. Pressure continues on market sentiment with additional confusion as earnings reporting ramps up” … https://www.regmedinvestors.com/articles/12310

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened negative at 3 up/29 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 9/22, 3 flats and 1 acquired, ending with a negative close of 7/25, 2 flats and 1 acquired;
  • Friday opened negative at 12 up/17 downs, 5 flats and 1 acquired, stayed negative at the mid-day at 3/29, 2 flat and 1 acquired, ending with a negative close of 3/28, 3 flats and 1 acquired;

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares jumping on “sudden” volume by 11 a.m. of 4,225 shares traded popping the stock +$0.70; Friday trading down -$0.68 with 103 shares traded after Thursday’s +$0.07 with 700 shares traded, Wednesday’s -$0.06 (after being down -$0.98) with 420 shares traded, Tuesday’s flat again with 200 shares traded and Monday’s flat with 1,899 shares traded

 

Key Metrics:

·         Tuesday - Sector volume was LOW with 2 of the 7-upside having higher than the 3-month average volume with LOW volume of 3 of 25-downside having higher than the 3-month average volume;

·         Monday was President’s Day, a holiday

·         Friday - Sector volume was LOW with 1 of the 3-upside having higher than the 3-month average volume with LOW volume of 4 of 28-downside having higher than the 3-month average volume

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday   the IBB closed down -0.70% and XBI closed down -0.79%
  • Monday was a holiday    

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +1.06 points or +3.82% at 28.81
  • Monday was a holiday 

 

Jumping with share pricing momentum (7 of 7):

·         Regenxbio (RGNX +$0.64),

·         Biostage (BSTG +$0.62),

·         Ultragenyx (RARE +$0.21),

·         Chinook therapeutics (KDNY +$0.10),

·         Voyager Therapeutics (VYGR +$0.09),

·         Athersys (ATHX +$0.068),

·         Sangamo Therapeutics (SGMO +$0.06),

Hammered in today’s market (10 of 25):

·         CRISPR Therapeutics (CRSP -$2.63),

·         Intellia Therapeutics (NTLA -$2.33),

·         Vericel (VCEL -$1.62),

·         ReNeuron (RENE.L -$1.50),

·         Global Blood Therapeutics (GBT -$1.30),

·         Homology Medicine (FIXX -$1.26),

·         Ionis Pharmaceuticals (IONS -$0.93),

·         Alnylam Pharmaceuticals (ALNY -$0.69),

·         BioLife Solutions (BLFS -$0.34),

·         Editas Medicine (EDIT -$0.19),

Closing Flat:

·         2 – uniQure NV (QURE), Fate Therapeutics (FATE) and 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

·         Tuesday closed negative with 7 incliners, 25 decliners, 2 flats and 1 acquired

·         Monday (2/21) was a holiday, President’s Day 

 

The BOTTOM LINE:  Cell and gene therapy sector stocks was locked again in the penalty boy over market pressures and lack of any confidence over geo-political “issues” and enhanced by an FDA clinical hold on FIXX – risk, risk and more risk as we run into earnings season’s busiest week.

We are just going with the flow as we trip and fall to the weekend …

Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.

Earnings’ reporting:

·         AxoGen AXGN) – Tuesday, 2/22

·         Global Blood Therapeutics (GBT) – Wednesday, 2/23

·         Sage Therapeutics (SAGE), Thursday, 2/24

·         Ionis Pharmaceuticals (IONS) - Thursday, 2/24

·         Sangamo Therapeutics (SGMO) - Thursday, 2/24

·         Editas Medicine (EDIT) - Thursday, 2/24

·         Fate therapeutics, Monday, 2/28

·         Regenxbio (RGNX), Tuesday, 2/1

·         Athersys (ATHX), Tuesday, 3/15

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.